Neuroguard IEP 3-in-1 Carotid Stent, Post-Dilation Balloon System with Integrated Embolic Protection
Contego Medical, Inc. · Decision date Nov 4, 2026
What did the FDA approve?
FDA records P240009/S006 as a supplement to PMA P240009, with the supplement type “Panel Track”. The recorded decision is approval, dated Nov 4, 2026.
FDA approval order statement
The Neuroguard IEP Direct 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection used in conjunction with the Neuroguard IEP Embolic Protection System is indicated for improving carotid luminal diameter in subjects at high risk for adverse events from carotid endarterectomy who require carotid revascularization and meet the criteria outlined below: Patients with = 50% symptomatic stenosis of the internal carotid artery (ICA) or common carotid artery (CCA) as determined by angiography, CTA, or duplex ultrasound or patients with = 70% asymptomatic stenosis of the internal carotid artery (ICA) or common carotid artery (CCA) as determined by angiography, CTA, or duplex ultrasound Patients with a reference vessel diameter of 4.0 - 8.0 mm At least 5 cm of atherosclerosis free space in the ipsilateral common carotid artery between the sheath insertion site and the proximal edge of the target lesion. This device is also indicated for post-dilation of the stent component with simultaneous capture and removal of embolic material.
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 4, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P240009/S006
- Regulatory pathway
- PMA supplement
- Applicant
- Contego Medical, Inc.
- Product code
- NIM
- Decision code
- APPR
- Decision date
- Nov 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, carotid.
- Applicant
- Contego Medical, Inc.
- Product code
- NIM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240009. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240009 · Original PMA
Neuroguard IEP 3-in-1 Carotid Stent, Post-Dilation Balloon System with Integrated Embolic Protection
P240009/S006 received
Application receipt date recorded by FDA.
P240009/S006 · FDA decision
Panel Track
Timeline entries are records held by MedtechLedger for P240009. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240009
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Contego Medical, Inc. | PMA approval | Oct 11, 2024 | FDA |
Explore the linked device profile
Other records with product code NIM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PROTEGE GPS AND PROTEGE RX CAROTID STENT SYSTEMSP060001/S060 | Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA approval | Jan 24, 2007 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Contego Medical, Inc.
- Headquarters
- Not reported
- Brand website
- contegomedical.com
- FDA applicant address
- 3801 Lake Boone Trl., Suite 100, Raleigh, NC, 27607
Sources and methodology
- Original FDA record: P240009/S006
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

